LoadingLoadingLoading32 funds hold it.Insiders net selling.
Net selling: insiders sold $38.9M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Oct 29, 2026
Financial period
Q3 2026
Earnings per share
$2.19 expected
Revenue
Company release
FY 2026 guidance
$31.00B to $31.30B
No comparable estimate
Estimates as of Nov 4, 2026
EPS expected
$0.02 to $1.40
Revenue expected
16 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Oct 29, 2026 | $2.55est. $2.19 | +16.23%beat | $8.30BCompany release | +6.8%from $7.77B |
| Jun 30, 2026Reported Aug 4, 2026 | -$6.75est. -$7.25 | +6.86%beat | $7.80BCompany release | +10.2%from $7.08B |
| Mar 31, 2026Reported May 7, 2026 | $2.03est. $1.91 | +6.24%beat | $6.96BCompany release | +4.4%from $6.67B |
| Dec 31, 2025Reported Feb 10, 2026 | $1.86est. $1.81 | +2.82%beat | $7.92BAlpha Vantage | +4.7%from $7.57B |
| Sep 30, 2025Reported Oct 30, 2025 | $2.47est. $2.14 | +15.42%beat | $7.77BSEC filing | +3.0%from $7.54B |
| Jun 30, 2025Reported Aug 7, 2025 | $2.01est. $1.95 | +3.08%beat | $7.08BSEC filing | +1.8%from $6.95B |
| Mar 31, 2025Reported Apr 24, 2025 | $1.81est. $1.78 | +1.69%beat | $6.67BSEC filing | -0.3%from $6.69B |
| Dec 31, 2024Reported Feb 11, 2025 | $1.90est. $1.70 | +11.73%beat | $7.57BAlpha Vantage | +6.4%from $7.11B |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $7.92B | $6.96B | $7.80B | $8.30B |
| Cost of what it sold | $1.62B | $1.45B | $1.58B | $1.57B |
| Gross profit | $6.30B | $5.51B | $6.22B | $6.73B |
| What it spent | ||||
| Research and development | $1.58B | $1.37B | $1.76B | $1.61B |
| Sales and admin | $652.0M | $553.0M | $1.92B | $695.0M |
| Other operating costs | $1.08B | $1.00B | $12.93B | $964.0M |
| Total operating expenses | $3.31B | $2.93B | $16.62B | $3.27B |
| What was left | ||||
| Operating profit | $2.99B | $2.69B | -$10.39B | $3.46B |
| Interest on debt | $255.0M | $240.0M | $247.0M | $269.0M |
| Profit before tax | $2.08B | $2.58B | -$10.25B | $3.06B |
| Tax | -$105.0M | $559.0M | $242.0M | $634.0M |
| Net profit | $2.18B | $2.02B | -$10.50B | $2.43B |
| EBITDA | $3.02B | $3.51B | -$9.31B | $4.07B |
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Zai Lab (ZLAB) Stock Looks Above Fair Value On Current Sales
NeutralNov 6CryoPort Q3 2026 Earnings Call Transcript
Leans bullishNov 5AASLD 2026: Gilead Eyes Wider Livdelzi Use As Phase III Data Bolster PBC Expansion Plans
BullishNov 5Processa Pharmaceuticals Shares Stockholder Letter Detailing Vidya Acquisition, VT-7208 Development, and Capital Structure
Leans bullishNov 5Did Earnings Beat Just Shift Gilead Sciences' (GILD) Investment Narrative?
Leans bullishNov 5Gilead's 11-Year Dividend Streak Holds as HIV Cash Flow Swells and Payout Ratio Stays Near 30%
BullishNov 5Gilead Sciences, Inc. $GILD Stock Sold by MH & Associates Securities Management Corp ADV
NeutralNov 58,560 Gilead Sciences, Inc. $GILD Shares Sold by Kelleher Financial Advisors
Leans bullishNov 5
